3,5-二甲基-1,2-恶唑-4-甲酰肼 | 412313-52-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3,5-二甲基-1,2-恶唑-4-甲酰肼
• 英文名称: 3,5-dimethylisoxazole-4-carbohydrazide
• 英文别名: 3,5-dimethyl-isoxazole-4-carboxylic acid hydrazide；3,5-Dimethyl-isoxazol-4-carbonsaeure-hydrazid；3.5-dimethyl-isoxazol-carbonsaeure-(4)-hydrazid；3,5-dimethyl-1,2-oxazole-4-carbohydrazide
• CAS: 412313-52-1
• 化学式: C₆H₉N₃O₂
• 分子量: 155.156
• InChiKey: CMXYQSABJKZEIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  81.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,5-二甲基-1,2-恶唑-4-甲酰肼 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 4-amino-5-(3,5-dimethyl-isoxazol-4-yl)-2,4-dihydro-[1,2,4]triazole-3-thione
  参考文献：
  名称：

  Sokolov,S.V.; Postovskii,I.Ya., Journal of general chemistry of the USSR, 1960, vol. 30, p. 1764 - 1769

  摘要：

  DOI：
• 作为产物：
  描述：

  3,5-二甲基异噁唑-4-甲酰氯 在 氯仿 、 一水合肼 作用下， 生成 3,5-二甲基-1,2-恶唑-4-甲酰肼
  参考文献：
  名称：

  Carrara et al., Gazzetta Chimica Italiana, 1952, vol. 82, p. 652,655, 660

  摘要：

  DOI：

文献信息

• [EN] P2X3 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR P2X3
  申请人：RECORDATI IND CHIMICA E FARMACEUTICA SPA

  公开号：WO2020011921A1

  公开（公告）日：2020-01-16

  This invention relates to compounds of formula (I); and their use as antagonists of P2X3 and P2X2/3 receptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of pain and chronic pain and tolerance to analgesic, respiratory disorders and dysfunctions, and treatment of overactive bladder, bladder pain syndrome, dysuria and in general in genitourinary diseases, cardiovascular disorders and more in general for the potential treatment of visceral organ diseases and disorders characterized by the involvement of P2X3 and P2X2/3 receptors.

  该发明涉及式(I)的化合物；以及它们作为P2X3和P2X2/3受体活性拮抗剂的用途，包括这些化合物的药物组合物，以及使用这些方法进行治疗。该发明的化合物可用于治疗和/或预防疼痛和慢性疼痛以及对镇痛药的耐受性、呼吸障碍和功能障碍、过度活跃的膀胱、膀胱疼痛综合征、排尿困难以及一般的泌尿系统疾病、心血管疾病以及一般的潜在治疗脏器疾病和通过P2X3和P2X2/3受体参与的疾病和障碍的治疗。
• Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners
  作者：Junwon Lee、Sung-Han Lee、Hee Jeong Seo、Eun-Jung Son、Suk Ho Lee、Myung Eun Jung、MinWoo Lee、Ho-Kyun Han、Jeongmin Kim、Jahyo Kang、Jinhwa Lee

  DOI：10.1016/j.bmc.2010.01.073

  日期：2010.3

  Novel C-aryl glucoside SGLT2 inhibitors containing 1,3,4-thiadiazole moieties were designed and synthesized. Among the compounds tested, biaryl-type compounds containing pyrazine 59, 2-furan 61, and 3-thiophene 71 showed the best in vitro inhibitory activities to date (IC50 = 3.51-7.03 nM) against SGLT2. A selected compound 61, demonstrated reasonable blood glucose-lowering effects, indicating that the information obtained from the SAR studies in this 1,3,4-thiadiazolylmethylphenyl glucoside series might help to design more active SGLT2 inhibitors that are structurally related. (C) 2010 Elsevier Ltd. All rights reserved.
• P2X3 RECEPTOR ANTAGONISTS
  申请人：Recordati Industria Chimica E Farmaceutica SPA

  公开号：EP3820566A1

  公开（公告）日：2021-05-19
• Sokolov,S.V.; Postovskii,I.Ya., Journal of general chemistry of the USSR, 1960, vol. 30, p. 1764 - 1769
  作者：Sokolov,S.V.、Postovskii,I.Ya.

  DOI：——

  日期：——
• Carrara et al., Gazzetta Chimica Italiana, 1952, vol. 82, p. 652,655, 660
  作者：Carrara et al.

  DOI：——

  日期：——